Three-year-old boy - A homozygote for familiar hypercholesterolemia;Trogodišnji dječak - Homozigot za porodičnu hiperkolesterolemiju

Lijecnicki Vjesnik

Volumn 129, Issue 5, 2007, Pages 130-133

  Dumić, Miroslav ^a,b   Uroić, Anita Špehar ^a   Francetić, Igor ^a   Puretić, Zvonimir ^a   Matišić, Danica ^b   Kes, Petar ^a   Mikecin, Martina ^c   Reiner, Željko ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b KBC Zagreb   (Croatia)

^c Privatna Pedijatrijska Ordinacija   (Croatia)

Author keywords

Cholesterol, LDL blood; Homozygote; Hyperlipoproteinemia type II genetics, blood, therapy

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR;

ARTICLE; CASE REPORT; GENETICS; HOMOZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MUTATION; PRESCHOOL CHILD;

CHILD, PRESCHOOL; HOMOZYGOTE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MUTATION; RECEPTORS, LDL;

EID: 34547159738     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ignacio García-Álvarez, Sergio Castitto, Pilar Mozas i sur. Differences in clinical presentation between subjects with a phenotype of familial hypercholesterolemia determined by defects in the LDL-receptor and defects in Apo B-100. Rev Esp Cardiol 2003;56:769-74.
2. Bertolini S, Cassanelli S, Garuti R i sur. Analysis of LDL receptor gene mutations in Italian patients with homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1999;19(2):408-18.
3. Reiner Ž. Genski poremećaji serumskih lipoproteina. Paediatr Croat 2005;49:133-9.
4. Lugo-Somolinos A, Sanchez JE. Xanthomas: a marker for hyperlipidemias. Bol Asoc Med P R 2003;95(4):12-6.
5. Srimannarayana J, Varma RS, Satheesh S, Anilkumar R, Balachander J. Supravalvular aortic stenosis and coronary ostial stenosis in homozygous familial hypercholesterolemia. Indian Heart J 2004;56:152-4.
6. Motulsky AG. Genetic aspects of familial hypercholesterolemia and its diagnosis. Arteriosclerosis 1989;9(Suppl 2):I3-7.
7. Goldstein JL, Dana SE, Brunschede GY, Brown MS. Genetic heterogeneity in familial hypercholesterolemia: evidence for two different mutations affecting functions of low-density lipoprotein receptor. Proc Natl Acad Sci USA 1975;72(3):1092-6.
8. Miserez AR, Keller U. Differences in the phenotypic characteristics of subjects with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15(10):1719-29.
9. Stein O, Weinstein DB, Stein Y, Steinberg D. Binding, internalization, and degradation of low density lipoprotein by normal human fibroblasts and by fibroblasts from a case of homozygous familial hypercholesterolemia. Proc Natl Acad Sci USA 1976;73(1):14-8.
10. Hoeg JM, Demosky SJ Jr, Schaefer EJ, Starzl TE, Brewer HB Jr. Characterization of hepatic low density lipoprotein binding and cholesterol metabolism in normal and homozygous familial hypercholesterolemic subjects. J Clin Invest 1984;73(2):429-36.
11. Pimstone SN, Defesche JC, Clee SM, Bakker HD, Hayden MR, Kastelein JJ. Differences in the phenotype between children with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997;17(5):826-33.
12. Pisciotta L, Oliva CP, Pes GM i sur. Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): A phenotypic comparison. Atherosclerosis 2005 Dec 8; [Epub ahead of print].
13. Rodenburg J, Wiegman A, Vissers MN, Kastelein JJP, Stalenhoef AFH. A boy with autosomal recessive hypercholesterolaemia. Neth J Med 2004;61 (3):89-93.
14. Semenkovich CF, Ostlund RE Jr, Levy RA, Osa SR. Low density lipoprotein receptor activity in homozygous familial hypercholesterolemia fibroblasts. J Biol Chem 1982;257(21):12857-6.
15. Zulewski H, Ninnis R, Miserez AR, Baumstark MW, Keller. VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100. J Lipid Res 1998;39(2):380-7.
16. Millar JS, Mangeais C, Ikewaki K i sur. Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production. Arterioscler Thromb Vasc Biol 2005;25(3):560-5.
17. Tremblay AJ, Lamarche B, Ruel IL i sur. Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation. J Lipid Res 2004;45(5):866-72.
18. Demetriou K, H'Maltezou E, Pierides AM. Familial homozygous hypercholesterolemia: effective long-term treatment with cascade double filtration plasmapheresis. Blood Purif 2001;19(3):308-13.
19. Naoumova RP, Thompson GR, Soutar AK. Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol 2004;15(4):413-22.
20. Gagne C, Gaudel D, Bruckert E. Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002;105(21):2469- 75.
21. Raal FJ, Marais AD, Klepack E, Lovalvo J, McLain R, Heinonen T. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis 2003;171(2):273-9.
22. McNamara DJ, Ahrens EH Jr, Kolb R i sur. Treatment of familial hypercholesterolemia by portacaval anastomosis: effect on cholesterol metabolism and pool sizes. Proc Natl Acad Sci USA 1983;80(2):564-8.
23. Moyle M, Tate B. Homozygous familial hypercholesterolaemia presenting with cutaneous xanthomas : response to liver transplantation. Austral J Dermatol 2004;45(4):226-8.
24. Lopez-Santamaria M, Migliazza L, Gamez M i sur. Liver transplantation in patients with homozygotic familial hypercholesterolemia previously treated by end-to-side portocaval shunt and ileal bypass. J Pediatr Surg 2000;35(4):630-3.
25. Sachais BS, Katz J, Ross J, Rader DJ. Long-term effects of LDL apheresis in patients with severe hypercholesterolemia. J Clin Apheresis 2005;20(4):252-5.
26. Meier P, Blanc E. Long-term efficacy of lipoprotein apheresis in homozygous familial hypercholesterolaemia. Nephrol Dial Transplant 2000; 15(5):738-40.
27. Hershcovici T, Schechner V, Orlin J, Harell D, Beigel Y. Effect of different LDL-apheresis methods on parameters involved in atherosclerosis. J Clin Apheresis 2004;19(2):90-7.
28. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force. Eur J Cardiovasc Prev Rehabil 2003; 10(Suppl 1):S2-S63.
29. Consensus Conference (1985) Lowering blood cholesterol to prevent heart disease. JAMA 1985;235:2080-6.